Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe

NCT06193239 is registered in ClinicalTrials.gov with Owlstone Ltd as lead sponsor.

NCT NCT06193239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe
Lead sponsor
Owlstone Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2023
Completion date
May 29, 2025
Enrollment
187 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer